Revolution Medicines director Barbara Weber resigns ahead of 2025 annual meeting due to Tango collaboration activation

Revolution Medicines, Inc.

Barbara Weber, M.D., resigned from Revolution Medicines board effective immediately prior to June 26, 2025 annual meeting.
Resignation triggered by activation of clinical study under collaboration with Tango Therapeutics, not due to any disagreement.
Dr. Weber also stepped down from Nominating and Corporate Governance Committee and R&D Committee.
The company has not yet named a replacement for the board vacancy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Barbara Weber, M.D.

Director

RVMD · Revolution Medicines, Inc.

Effective: 2025-06-26
Filed: June 18, 2025, 7:59 PM ET

On June 18, 2025, Barbara Weber, M.D., communicated her decision to resign from the board of directors (the “Board”) of Revolution Medicines, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Barbara Weber, M.D. resigned as Director at Revolution Medicines, Inc..

Action: resigned
Role: Director

Exact text from the filing

On June 18, 2025, Barbara Weber, M.D., communicated her decision to resign from the board of directors (the “Board”) of Revolution Medicines, Inc.

View on SEC.gov

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-142735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.